Company
Eli Lilly
NYSE:LLY
Tirzepatide + oral orforglipron; XPRIZE Healthspan sponsor.
At a glance
- Listing
- NYSE:LLY
- Category
- GLP-1 and metabolic
- Headquarters
- Indianapolis
- Market cap
- ~US$1.15T
Thesis
Why it is in this universe
- Category
- GLP-1 and metabolic
- Market
- Global
- Recent inflection
- Oral orforglipron ("Foundayo") FDA-approved 1 Apr 2026.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | NYSE |
| Ticker | NYSE:LLY |
| Secondary listing | None |
| Market cap | ~US$1.15T |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Indianapolis
- Website
- No site on file
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
Oral orforglipron ("Foundayo") FDA-approved 1 Apr 2026.
Common questions
- Why does variis track Eli Lilly?
- Tirzepatide + oral orforglipron; XPRIZE Healthspan sponsor.
- Is Eli Lilly publicly listed?
- Yes. It trades as NYSE:NYSE:LLY. Market capitalisation is in the ~US$1.15T range, recorded as a dated snapshot rather than a live quote.
- Where is Eli Lilly based?
- Indianapolis
- Is Eli Lilly still trading?
- Eli Lilly is recorded as actively trading.
Latest moves
Dated developments variis is tracking.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
No source is on file for this company yet. Treat everything above as unverified until one is.
Every entity profile on variis is sourced. Not investment advice.